



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

will mean latecomers to treatment are not penalised with a refractory illness. As we have learnt over the past two decades, even punctual treatment when symptoms first arise continues to be too late when it comes to psychosis.

LP reports grants and personal fees from Janssen Canada and Otsuka Canada, grants from Sunovion, and personal fees from SPMM Course UK and The Canadian Psychiatric Association, outside of the submitted work. RK declares no competing interests.

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Lena Palaniyappan, *Rajeev Krishnadas
rajeev.krishnadas@glasgow.ac.uk

Robarts Research Institute (LP) and Department of Psychiatry (LP), University of Western Ontario, London, ON, Canada; Lawson Health Research Institute, London, ON, Canada (LP); ESTEEM, NHS Greater Glasgow and Clyde, Glasgow, UK (RK); and Institute of Neuroscience and Psychology, University of Glasgow, Glasgow G12 8QB, UK (RK)

- Lally J, Ajnakina O, Stubbs B, et al. Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies. *Br J Psychiatry* 2017; **211**: 350–58.
- Jonas KG, Fochtmann LJ, Perlman G, et al. Lead-time bias confounds association between duration of untreated psychosis and illness course in schizophrenia. *Am J Psychiatry* 2020; **177**: 327–34.
- Oliver D, Davies C, Crossland G, et al. Can we reduce the duration of untreated psychosis? A systematic review and meta-analysis of controlled interventional studies. *Schizophr Bull* 2018; **44**: 1362–72.
- Drake RJ, Husain N, Marshall M, et al. Effect of delaying treatment of first-episode psychosis on symptoms and social outcomes: a longitudinal analysis and modelling study. *Lancet Psychiatry* 2020; 7: 602–10.
- Donde C, Vignaud P, Poulet E, Brunelin J, Haesebaert F. Management of depression in patients with schizophrenia spectrum disorders: a critical review of international guidelines. *Acta Psychiatr Scand* 2018; **138**: 289–99.
- McGlashan TH. Is active psychosis neurotoxic? *Schizophr Bull* 2006; **32**: 609–13.
- Dempster K, Jeon P, MacKinley M, Williamson P, Theberge J, Palaniyappan L. Early treatment response in first episode psychosis: a 7-T magnetic resonance spectroscopic study of glutathione and glutamate. *Mol Psychiatry* 2020; published online March 24. DOI:10.1038/s41380-020-0704-x.
- Maximo JO, Nelson EA, Armstrong WP, Kraguljac NV, Lahti AC. Duration of untreated psychosis correlates with brain connectivity and morphology in medication-naïve patients with first-episode psychosis. *Biol Psychiatry Cogn Neurosci Neuroimaging* 2020; **5**: 231–38.
- Palaniyappan L. Inefficient neural system stabilization: a theory of spontaneous resolutions and recurrent relapses in psychosis. *J Psychiatry Neurosci* 2019; **44**: 367–83.
- Leighton SP, Upthegrove R, Krishnadas R, et al. Development and validation of multivariable prediction models of remission, recovery, and quality of life outcomes in people with first episode psychosis: a machine learning approach. *Lancet Digital Health* 2019; **1**: e261–70.

What can psychiatrists learn from SARS and MERS outbreaks?

While standard care for patients with psychiatric disorders must continue during the current COVID-19 pandemic, psychiatrists also need to treat psychiatric complications of patients with this new disease. An estimation of expected prevalences of psychiatric disorders occurring in this group would help to redistribute mental health personnel between old and new tasks to serve the needs of both groups optimally. In *The Lancet Psychiatry*, Jonathan Rogers and colleagues¹ report the results of their systematic review and meta-analysis of psychiatric sequelae in patients admitted to hospital with severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19 in the acute and post-illness stages of disease. The systematic review showed that most patients with SARS or MERS do not develop psychiatric disorders, but a significant minority exhibits confusion (36 [27.9%; 95% CI 20.5–36.0] of 129 patients), depressed mood (42 [32.6%; 24.7–40.9] of 129), anxiety (46 [35.7%; 27.6–44.2] of 129), impaired memory (44 [34.1%; 26.2–42.5] of 129), and insomnia (54 [41.9%; 22.5–50.5] of 129). The meta-analysis showed that the point prevalence in the post-illness stage was 32.2% (95% CI 23.7–42.0) for

post-traumatic stress disorder, 14.9% (12.1–18.2) for depression, and 14.8% (11.1–19.4) for anxiety.

As the COVID-19 pandemic is so recent and ongoing, few studies reported on psychiatric disorders complicating this particular disease and those that did reported only short-term aspects. Rogers and colleagues circumvented this knowledge gap by taking together the few studies on psychiatric disorders in patients with COVID-19 with the much larger body of literature on psychiatric disorders accompanying two previous coronavirus epidemics: the 2002 SARS and the 2012 MERS outbreaks. From a biological perspective, it makes sense to merge data on SARS coronavirus 2 (SARS-CoV-2), which causes COVID-19, infections with those of SARS coronavirus (SARS-CoV) and MERS coronavirus (MERS-CoV) infections because resemblance between these three types of coronaviruses is high.² SARS-CoV-2 is structurally and genetically highly homologous to MERS-CoV (>50% similarity) and SARS-CoV (>79% similarity).³ Even the spike proteins that SARS-CoV and SARS-CoV-2 use to attach to the target cell membrane (spike protein S, which interacts with the angiotensin-converting enzyme 2 receptor) are



Published Online
May 18, 2020
[https://doi.org/10.1016/S2215-0366\(20\)30219-4](https://doi.org/10.1016/S2215-0366(20)30219-4)

See [Articles](#) page 611

largely similar.⁴ Coronaviruses have been shown to be potentially neuroinvasive, neurotropic, and neurovirulent. For SARS-CoV and MERS-CoV, the presence of virus in the brain has been confirmed with RT-PCR, immunohistochemistry, and in-situ hybridisation.³ Such confirmations have not yet been provided for SARS-CoV-2, but symptoms such as confusion, seizures, and anosmia during acute infection might reflect CNS involvement. Thus, in terms of virus properties, SARS-CoV-2, SARS-CoV, and MERS-CoV are largely comparable.⁴

However, treatment of patients admitted to the hospital for SARS-CoV-2 infection seems to be different from treatment of those admitted for SARS-CoV and MERS-CoV infections. Furthermore, the social situation to which COVID-19 survivors return is completely different from that of SARS and MERS survivors. These differences are relevant for the prevalence of psychiatric disorders in both acute and post-illness stages. Patients with COVID-19 who are admitted to hospital might be older than patients admitted for SARS^{2,4} (although not all studies show this⁵), and the mean duration of their stay in the intensive care unit (ICU) is longer.^{2,4} In the COVID-19 era, unlike the previous SARS and MERS outbreaks, fear for shortage of medical facilities such as ventilators can further increase stress. All three factors increase the risk for psychiatric complications such as anxiety and delirium in the acute stage for patients with COVID-19 compared with those with SARS or MERS. Staying at the ICU is a risk factor for developing psychiatric disorders by itself. In 2018, a large study among almost 5000 ICU survivors showed that prevalence of post-traumatic stress disorder was 46%, that of anxiety was 40%, and that of depression was 22%.⁶ These prevalences are well above the upper ranges of the confidence intervals reported by Rogers and colleagues. As prolonged ICU stay and use of mechanical ventilation are both risk factors for psychiatric disorders,⁷ patients with COVID-19 who need admission to an ICU are an ultra-high-risk group for developing acute psychiatric disorders, especially delirium.⁸

Finally, COVID-19 survivors, unlike SARS and MERS survivors, return to a society in deep economic crisis, with shortage of basic needs such as food in

some countries and other countries still in lockdown and enforcing physical isolation. These social adversities will keep stress levels after somatic recovery high, and further increase patients' risk for long-term psychiatric complications such as anxiety and depression.

We conclude that findings from previous coronavirus outbreaks are useful,⁴ but might not be exact predictors of prevalences of psychiatric complications for patients with COVID-19. The warning from Rogers and colleagues that we should prepare to treat large numbers of patients with COVID-19 who go on to develop delirium, post-traumatic stress disorder, anxiety, and depression is an important message for the psychiatric community. Reported prevalence estimates in this Article should be interpreted with caution, as true numbers of both acute and long-term psychiatric disorders for patients with COVID-19 might be considerably higher.

We declare no competing interests.

Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

**Iris E Sommer, P Roberto Bakker*
i.e.c.sommer@umcg.nl

Department of Biomedical Sciences of Cells and Systems, Rijksuniversiteit Groningen, University Medical Center Groningen, Groningen, Netherlands (IES); and Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, Netherlands (PRB)

- 1 Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. *Lancet Psychiatry* 2020; published online May 18. [https://doi.org/10.1016/S2215-0366\(20\)30203-0](https://doi.org/10.1016/S2215-0366(20)30203-0).
- 2 Adhikari SP, Meng S, Wu YJ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. *Infect Dis Poverty* 2020; **9**: 29.
- 3 Desforges M, Le Coupanec A, et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? *Viruses* 2019; **12**: 14.
- 4 Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? *Clin Microbiol Infect* 2020; published online March 28. DOI:10.1016/j.cmi.2020.03.026.
- 5 Li TS, Gomersall CD, Joynt GM, Chan DP, Leung P, Hui DS. Long-term outcome of acute respiratory distress syndrome caused by severe acute respiratory syndrome (SARS): an observational study. *Crit Care Resusc* 2006; **4**: 302–08.
- 6 Hatch R, Young D, Barber V, Griffiths J, Harrison DA, Watkinson P. Anxiety, depression and post traumatic stress disorder after critical illness: a UK-wide prospective cohort study. *Crit Care* 2018; **22**: 310.
- 7 Jackson P, Khan A. Delirium in critically ill patients. *Crit Care Clin* 2015; **3**: 589–603.
- 8 Kotfis K, Williams Roberson S, Wilson JE, Dabrowski W, Pun BT, Ely EW. COVID-19: ICU delirium management during SARS-CoV-2 pandemic. *Crit Care* 2020; **24**: 176.